Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Fish and Richardson
Express Scripts
Teva
UBS
Federal Trade Commission
McKesson
AstraZeneca
Accenture

Generated: May 23, 2018

DrugPatentWatch Database Preview

OXANDRIN Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Oxandrin, and what generic alternatives are available?

Oxandrin is a drug marketed by Gemini Labs Llc and is included in one NDA.

The generic ingredient in OXANDRIN is oxandrolone. There are ten drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the oxandrolone profile page.
Summary for OXANDRIN
Drug patent expirations by year for OXANDRIN
Medical Subject Heading (MeSH) Categories for OXANDRIN
Synonyms for OXANDRIN
(1S,2S,7S,10R,11S,14S,15S)-14-hydroxy-2,14,15-trimethyl-4-oxatetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadecan-5-one
(1S,2S,7S,10R,11S,14S,15S)-14-HYDROXY-2,14,15-TRIMETHYL-4-OXATETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADECAN-5-ONE
(1S,3aS,3bR,5aS,9aS,9bS,11aS)-1-hydroxy-1,9a,11a-trimethyl-2,3,3a,3b,4,5,5a,6,9,9b,10,11-dodecahydroindeno[4,5-h]isochromen-7-one
(4aS,4bS,6aS,7S,9aS,9bR,11aS)-7-hydroxy-4a,6a,7-trimethyltetradecahydroindeno[4,5-h]isochromen-2(1H)-one
17-beta-hydroxy-17-methyl-2-oxa-androstan-3-one
17-beta-hydroxy-17-methyl-2-oxa-androstan-3-one (9CI)
17alpha-Methyl-17beta-hydroxy-2-oxa-5alpha-androstan-3-one
17beta-Hydroxy-17-methyl-2-oxa-5alpha-androstan-3-one
17beta-Hydroxy-17alpha-methyl-2-oxa-5alpha-androstan-3-one
198O944
2-Oxa-5-alpha-androstan-3-one, 17-beta-hydroxy-17-methyl-
2-Oxa-5alpha-androstan-3-one, 17beta-hydroxy-17-methyl-
2-Oxa-5alpha-androstan-3-one, 17beta-hydroxy-17-methyl- (8CI)
2-Oxa-5alpha-androstan-3-one, 17beta-hydroxy-17-methyl-(8CI)
2-Oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5-alpha,17-beta)-
2-Oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5-alpha,17-beta)- (9CI)
2-Oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5-alpha,17-beta)-(9CI)
2-Oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5alpha,17beta)-
5-A-ANDROSTAN-2-OXA-17-A-METHYL-17BETA-OL-3-ONE
5-ALPHA-ANDROSTAN-2-OXA-17-ALPHA-METHYL-17BETA-OL-3-ONE
53-39-4
7H6TM3CT4L
8075 C. B
8075 C. B.
8075 C.B
8075 C.B.
8075 CB
AB01559948-01
AB04708
AC-14975
AC1L1LBY
AKOS025401400
Ambap53-39-4
AN-6689
Anavar
Anavar (TN)
AOB87477
BC208393
C-19066
C07346
C19H30O3
CC-33403
CCG-220110
CHEBI:7820
CHEMBL1200436
CS-2944
D00462
D0U3GL
DB00621
Dodecahydro-3-hydroxy-6-(hydroxy-methyl)-3,3a,6-trimethyl-1H-benz(e)indene-7-acetic acid delta-lactone
DTXSID8023399
EINECS 200-172-9
GTPL7092
HSDB 3373
HY-B0707
Lonavar
LS-98540
NSC 67068
Ossandrolone
Ossandrolone [DCIT]
oxandren
Oxandrin (TN)
Oxandrin, Anavar, Oxandrolone
Oxandrolon
Oxandrolona
Oxandrolona [INN-Spanish]
OXANDROLONE
Oxandrolone (JAN/USP/INN)
Oxandrolone [USAN:INN:BAN:JAN]
Oxandrolone [USAN:USP:INN:BAN:JAN]
Oxandrolone, >=98% (HPLC)
Oxandrolonum
Oxandrolonum [INN-Latin]
PL005651
Protivar
Provitar
QSLJIVKCVHQPLV-PEMPUTJUSA-N
SC 11585
SC-11585
SCHEMBL148881
SR-01000872645
SR-01000872645-1
TL8003512
UNII-7H6TM3CT4L
Vasorome
W-105740
ZINC3813047

US Patents and Regulatory Information for OXANDRIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gemini Labs Llc OXANDRIN oxandrolone TABLET;ORAL 013718-001 Approved Prior to Jan 1, 1982 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Gemini Labs Llc OXANDRIN oxandrolone TABLET;ORAL 013718-002 Nov 5, 2001 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for OXANDRIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gemini Labs Llc OXANDRIN oxandrolone TABLET;ORAL 013718-002 Nov 5, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Gemini Labs Llc OXANDRIN oxandrolone TABLET;ORAL 013718-001 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Gemini Labs Llc OXANDRIN oxandrolone TABLET;ORAL 013718-001 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Gemini Labs Llc OXANDRIN oxandrolone TABLET;ORAL 013718-002 Nov 5, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for OXANDRIN
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 2.5 mg and 10 mg ➤ Subscribe 2006-06-19

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Fish and Richardson
McKinsey
Boehringer Ingelheim
Chubb
Dow
Daiichi Sankyo
Queensland Health
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.